Kuehne+Nagel will support the worldwide distribution of vaccine doses from Moderna’s international supply chain, based in Europe.
Kuehne+Nagel Group is one of the world’s leading logistics companies. Its strong market position lies in sea logistics, air logistics, road logistics and contract logistics, with a clear focus on integrated logistics solutions.
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Kuehne+Nagel, a world-leading logistics company, today announced that they have agreed an international supply chain arrangement to provide distribution and storage of the Covid-19 Vaccine Moderna. This announcement follows the granting of conditional marketing authorisation by the European Medicines Agency (EMA) for Covid-19 Vaccine Moderna.
Dan Staner, Vice President Head of EMEA region, Moderna Inc. said “we are proud to be partnering with Kuehne+Nagel from Europe to support the distribution of vaccines to global citizens. Following the recent approvals, this is another step closer to resolving the pandemic and an exciting time for both our companies and everyone involved.”
The arrangement includes distribution and warehousing of the vaccine from Kuehne+Nagel’s pharma hub in Europe. Kuehne+Nagel will use its network of more than 230 operations worldwide to distribute the vaccine via road and air. In Europe alone, the company operates its own fleet of over 200 dedicated pharmaceutical transport vehicles. At all stages of transport and storage, product integrity at the required temperature of -20°C will be maintained.
Kuehne+Nagel has also signed partnerships with authorities in several countries for local storage and last-mile distribution, such in Germany’s most populous state, North Rhine-Westphalia.